Zydus Cadila gets USFDA approval for skin ointment
Zydus Cadila on Wednesday informed the bourses that it has received the final approval from USFDA to market Clobetasol Propionate Cream.
Clobetasol Propionate steroid is used to treat inflammation and itching caused by a number of skin conditions such as allergic reactions, eczema and psoriasis.
During the recent quarter Q1FY19, the company has launched 9 new products in the US and 19 products in India. The company filed 3 additional ANDAs with the USFDA and received 13 ANDA approvals, during the latest quarter. As of date, the company has 222 approvals.
On Wednesday, the stock of Cadila Healthcare opened at Rs. 382.60 per share and made an intraday high and low of Rs. 383.90 and Rs. 375.95, respectively, on the BSE.